Recent achievements and future directions of anti-obesity medications
Open Access
- 9 November 2024
- journal article
- review article
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 47, 101100
Abstract
No abstract availableKeywords
This publication has 128 references indexed in Scilit:
- Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?JAMA, 2024
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 DiabetesJAMA, 2023
- Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 DiabetesJAMA Network Open, 2023
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2022
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without DiabetesJAMA, 2022
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2018
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 DiabetesJAMA, 2015